217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Naoto T. Ueno, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Aleix Prat, Junji Tsurutani, Y.H. Park, H. S. Rugo, Binghe Xu,

Annals of Oncology · 2022 · 21 citations · 1 references

DOIFull text

Open access

Concepts

References

1